Virus therapy tested as new weapon against tough lung cancers
NCT ID NCT06125197
Summary
This early-stage study is testing the safety of a new two-part treatment for advanced non-small cell lung cancer that has stopped responding to standard immunotherapy. The treatment combines a modified virus designed to attack tumors with an existing immunotherapy drug (pembrolizumab). The trial will enroll about 22 patients to find the safest and most effective dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92658, United States
-
UCLA Jonsson Comprehensive Cancer Center
Santa Monica, California, 90404, United States
Conditions
Explore the condition pages connected to this study.